Alkermes Public Limited Company (ALKS)

Alkermes announced positive Phase 2 data for alixorexton (ALKS 2680) in 2025, evaluating it for narcolepsy type 1, and initiated a Phase 2 study for idiopathic hypersomnia, contributing to a raised 2025 financial outlook. In November 2025, Alkermes agreed to acquire Avadel Pharmaceuticals for up to $2.37 billion, with shareholders approving the acquisition in January 2026. The company's financial expectations for 2024 and 2025 assumed Q1 seasonality, with growth expected in the second quarter and beyond. In January 2026, Alkermes received breakthrough therapy designation from the FDA for alixorexton. Over the past year, Alkermes Plc (ALKS) has experienced a -2.28% change in its stock price, with a 52-week range between $25.17 and $36.45.

Alkermes Plc experiences demand seasonality, with financial expectations for 2024 and 2025 anticipating "Q1 seasonality" for its proprietary products, with growth typically observed in the second quarter and beyond. VIVITROL's net sales are subject to "normal seasonal trends in patient flow." The first quarter generally sees "wholesaler inventory normalization related to the extra order cycle in Q4 and usual first quarter inventory drawdown patterns, typical Q1 patient copay and deductible reset dynamics, and historical demand patterns" which impact net sales from its proprietary commercial product portfolio.

Alkermes Plc is a global biopharmaceutical company focused on developing medicines for psychiatric and neurological disorders. The company's core business segments include proprietary products and partnered products. Major products include LYBALVI for schizophrenia and bipolar I disorder, ARISTADA/ARISTADA INITIO for schizophrenia, and VIVITROL for alcohol and opioid dependence. Alkermes also has partnered products like VUMERITY for multiple sclerosis and RISPERDAL CONSTA and Invega products for schizophrenia and bipolar I disorder. The company is advancing a pipeline of clinical and preclinical candidates for neurological disorders, including alixorexton (ALKS 2680) for narcolepsy and idiopathic hypersomnia.

Alkermes Plc is headquartered in Dublin, Ireland, with an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. The company has global operations, with primary revenue from the U.S., as well as a presence in Ireland and other international markets. In May 2024, Alkermes sold its development and manufacturing facility in Athlone, Ireland, to Novo Nordisk.

Alkermes Plc was recognized as one of the "Best Workplaces in BioPharma™ 2024," a "Top Place to Work in Massachusetts 2024," and a "Best Place to Work in Greater Cincinnati" in 2024.

Institutional investors hold approximately 95.21% of Alkermes Plc's shares, with major holders including BlackRock, Inc., Vanguard Group Inc, Price T Rowe Associates Inc /Md/, and State Street Corp. Individual investors hold approximately 1.4% of the company's shares.